Back to dashboard
CommercialPrior AuthMedium impact

State and School Employees' Health Insurance Plan - Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)

Blue Cross & Blue Shield of Mississippi·MS · Rheumatology, Nephrology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

New medical policy establishes coverage criteria for Benlysta (belimumab) for systemic lupus erythematosus and lupus nephritis treatment under State and School Employees' Health Insurance Plan. Saphnelo (anifrolumab-fnia) is deemed not medically necessary with formulary alternatives preferred.

Action Required

Action needed
Immediately: Update prior authorization processes for Benlysta (belimumab) to require documentation of SLE/lupus nephritis diagnosis, previous treatment failures with hydroxychloroquine and immunosuppressive agents, specialist consultation, and kidney biopsy results for lupus nephritis cases. Configure system to flag Saphnelo requests as not medically necessary. Train staff on 6-month initial approval and 12-month renewal timeframes.

Related policy hubs